This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lewis, J. P. Search for Related Content PubMed PubMed Citation Articles by Lewis, J. P.

Breast Cancer

An Interpretation of the EBCTCG Data

Departments of Medicine and Pathology, School of Medicine, University of California, Davis, California, USA

Key Words. Breast Cancer • Adjuvant therapy • Carryover benefit

Correspondence: Jerry P. Lewis, M.D., 1198 Muirfield Drive, West Chester, Pennsylvania 19382, USA. Telephone: 610-793-3665; e-mail: jerrymarguerite{at}comcast.net

Published data and figures from the Early Breast Cancer Clinical Trialists' Collaborative Group are explored and interpreted as supporting a concept that the prime impact of adjuvant hormonal and polychemotherapy therapy is on soon-to-emerge tumors, with the timing of benefit accrual being mostly limited to the time of drug administration. Nevertheless, once benefit in reducing recurrence occurs, the benefit is maintained for years. Depending on how this is viewed, there may or may not be a carryover effect of these therapies in the setting of adjuvant breast cancer.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				D. Berry Commentary: The Hazards of Survival Comparisons Oncologist, May 1, 2007; 12(5): 510 - 511. [Full Text] [PDF]